Thomas Weimbs, Ph.D.
Affiliations: | 1984-1990 | Department of Chemistry | University of Cologne, |
| 1989-1993 | Department of Biochemistry, Medical School | University of Cologne, Köln, Nordrhein-Westfalen, Germany | |
| 1993-1999 | Department of Anatomy | University of California, San Francisco, San Francisco, CA | |
| 1999-2005 | Department of Cell Biology | The Cleveland Clinic, Cleveland, OH, United States | |
| 2005- | Department of Molecular, Cellular, and Developmental Biology | University of California, Santa Barbara, Santa Barbara, CA, United States |
Area:
polycystic kidney disease, membrane trafficking, SNARE membrane fusion proteinsWebsite:
https://labs.mcdb.ucsb.edu/weimbs/thomas/Google:
"Thomas Weimbs"Mean distance: 53433
Parents
Sign in to add mentor| Wilhelm Stoffel | grad student | 1990-1993 | University of Cologne |
| Keith E. Mostov | post-doc | 1994-1999 | UCSF (Cell Biology Tree) |
Children
Sign in to add trainee| Hannah Pellegrini | grad student | 2017- | UC Santa Barbara |
| Elizabeth Sharpe | grad student | 2018- | UC Santa Barbara |
| Nickolas Holznecht | grad student | 2020- | UC Santa Barbara |
| Nikunj Sharma | grad student | 2002-2007 | Cleveland State University |
| Shivakumar Vasanth | grad student | 2003-2007 | Kent State |
| Jeffrey J. Talbot | grad student | 2013 | UC Santa Barbara |
| Nicholas Doerr | grad student | 2007-2014 | UC Santa Barbara |
| Erin Olsan | grad student | 2007-2014 | UC Santa Barbara |
| Adrian Giovannone | grad student | 2008-2014 | UC Santa Barbara |
| Kevin Kipp | grad student | 2011-2016 | UC Santa Barbara |
| Jacob Torres | grad student | 2011-2017 | UC Santa Barbara |
| Pallavi Bhattaram | post-doc | 2004-2006 | UC Santa Barbara |
| Elena Reales | post-doc | 2006-2010 | UC Santa Barbara |
| Jonathan Shillingford | post-doc | 2003-2012 | UC Santa Barbara |
| Christine Winterstein | post-doc | 2007-2012 | UC Santa Barbara |
| Guangyi Liu | post-doc | 2015-2016 | UC Santa Barbara |
| Sebastian Strubl | post-doc | 2019-2022 | UC Santa Barbara |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Messing M, Torres JA, Holznecht N, et al. (2024) Trigger Warning: How Modern Diet, Lifestyle, and Environment Pull the Trigger on Autosomal Dominant Polycystic Kidney Disease Progression. Nutrients. 16 |
| Torres JA, Holznecht N, Asplund DA, et al. (2024) β-hydroxybutyrate recapitulates the beneficial effects of ketogenic metabolic therapy in polycystic kidney disease. Iscience. 27: 110773 |
| Weimbs T, Saville J, Kalantar-Zadeh K. (2023) Ketogenic metabolic therapy for chronic kidney disease - the pro part. Clinical Kidney Journal. 17: sfad273 |
| Torres JA, Holznecht N, Asplund DA, et al. (2023) A Combination of ß-Hydroxybutyrate and Citrate Ameliorates Disease Progression in a Rat Model of Polycystic Kidney Disease. American Journal of Physiology. Renal Physiology |
| Cukoski S, Lindemann CH, Arjune S, et al. (2023) Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trial. Cell Reports. Medicine. 101283 |
| Pellegrini H, Sharpe EH, Liu G, et al. (2023) Cleavage fragments of the C-terminal tail of polycystin-1 are regulated by oxidative stress and induce mitochondrial dysfunction. The Journal of Biological Chemistry. 105158 |
| Akbari M, West JD, Doerr N, et al. (2022) Restoration of atypical protein kinase C ζ function in autosomal dominant polycystic kidney disease ameliorates disease progression. Proceedings of the National Academy of Sciences of the United States of America. 119: e2121267119 |
| Tonum K, Srimai N, Chabang N, et al. (2022) Pharmacological Effects of Panduratin A on Renal Cyst Development in In Vitro and In Vivo Models of Polycystic Kidney Disease. International Journal of Molecular Sciences. 23 |
| Strubl S, Oehm S, Torres JA, et al. (2021) Ketogenic dietary interventions in autosomal dominant polycystic kidney disease-a retrospective case series study: first insights into feasibility, safety and effects. Clinical Kidney Journal. 15: 1079-1092 |
| Giovannone AJ, Reales E, Bhattaram P, et al. (2020) The H domain of syntaxin 3 is a ubiquitin binding domain. Scientific Reports. 10: 21350 |